Solid Tumor Cancer PBMC
Solid Tumor Cancer PBMC samples are isolated from donors with clinically diagnosed solid tumours, processed within 24 hours and cryopreserved in CryoStor CS10. Suited to T-cell exhaustion immunophenotyping, checkpoint-inhibitor potency work, MDSC and regulatory T-cell suppression assays, and patient-derived effector cell sourcing for engager and CAR programmes. Stratification by indication, stage, treatment and response, with matched healthy controls.
Solid Tumor Cancer PBMC for Immuno-Oncology Research
Solid Tumor Cancer PBMC samples are collected from IRB-consented donors clinically diagnosed with solid-tumour cancers, processed within 24 hours of collection and preserved in CryoStor® CS10 to maintain viability and function. These cryopreserved peripheral blood mononuclear cells support study of tumour-immune interactions, immune-checkpoint regulation and systemic immune responses across a range of solid tumours, in cell counts from 5 million to 2 billion.
Why Solid Tumour PBMC for Immuno-Oncology Research
Solid tumours are neoplastic diseases, and the peripheral immune compartment of a cancer patient is systematically different from that of a healthy donor. Tumours shape host immunity through secreted factors, chronic antigen exposure and expansion of suppressive cell populations, and those changes are detectable in circulating mononuclear cells. Healthy-donor PBMCs cannot reproduce this state, which is why disease-state cells matter for immuno-oncology assay development.
- T-cell exhaustion — chronic tumour antigen exposure drives inhibitory receptor expression including PD-1, TIM-3, LAG-3 and TIGIT, with reduced proliferative and cytotoxic capacity.
- Suppressive myeloid expansion — myeloid-derived suppressor cells expand in the circulation of cancer patients and actively inhibit T-cell function, making them both a confounder and a target.
- Regulatory T-cell expansion — increased Treg frequency and suppressive capacity contribute to peripheral tolerance of the tumour.
- Immune-checkpoint axis — PD-1 and CTLA-4 expression on donor T cells is the direct substrate for checkpoint-inhibitor mechanism-of-action and potency work.
- NK cell and effector function — cytotoxicity and antibody-dependent cellular cytotoxicity capacity in patient-derived effectors is the realistic setting for antibody and engager potency assays.
- Cellular specimen advantage — because PBMCs are viable nucleated cells, flow cytometry, killing and suppression assays, antigen-specific stimulation, single-cell transcriptomics and TCR repertoire sequencing are all available; none are possible in an acellular plasma or serum product.
Donor Stratification Available
- Tumour indication — breast, lung, colorectal, pancreatic, prostate, ovarian, renal and other solid tumours, subject to availability
- Stage and disease extent — localised, locally advanced, and metastatic disease
- Treatment status — treatment-naive, on immune-checkpoint inhibitor therapy, on chemotherapy or targeted therapy, and post-treatment donors
- Response and trajectory — responding versus progressing donors; serial draws from the same donor where collected
- Molecular and biomarker context — indication-specific markers such as HER2, hormone receptor, EGFR/ALK or microsatellite status where documented
- Matched healthy controls available, drawn on the same protocol and matched for age, sex and ethnicity
Product Features
- Research Use Only (RUO), cryopreserved solid-tumour PBMC samples
- Clinically confirmed solid-tumour cancer donors
- Available in cell counts ranging from 5 million to 2 billion
- Processed within 24 hours of collection
- Preserved using CryoStor® CS10 freezing media
- IRB-approved protocols and electronic informed consent
- Screening (LeukoLot™) available prior to bulk orders
De-identified Donor Data
- Verified solid-tumour cancer diagnosis
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported allergies and infectious disease history
- Indication, stage and treatment context reported per lot where captured
- Additional tumour-type and clinical data available on request
Applications
- T-cell exhaustion and inhibitory receptor immunophenotyping
- Immune-checkpoint inhibitor mechanism-of-action and potency assays
- Myeloid-derived suppressor cell and regulatory T-cell characterisation and suppression assays
- NK cell cytotoxicity and antibody-dependent cellular cytotoxicity assays
- Patient-derived effector cell sourcing for bispecific engager and CAR construct potency work
- Single-cell transcriptomic and TCR repertoire profiling in cancer cohorts
- Drug screening and ex vivo pharmacology in disease-state immune cells
- Biomarker discovery and validation for response and resistance to immunotherapy
Other Solid Tumor Cancer Specimen Types
- Solid Tumor Cancer Plasma
- Solid Tumor Cancer Serum
- Solid Tumor Cancer Whole Blood
- Solid Tumor Cancer Leukopak
Compliance and Quality Assurance
- IRB-approved collections and protocols
- 21 CFR Part 11-compliant e-consent
- HIPAA-compliant donor data protection
Ordering & Customization
Solid Tumor Cancer PBMC samples ship on dry ice in standard or custom aliquots. For pricing, international orders or regulatory documentation, contact learnmore@sanguinebio.com. To compare collection formats, browse all human PBMCs or request a custom disease-state collection.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
PBMC
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.